Erudio Healtherudio.com
Sponsor
Bayer trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Bayer: ARASTEP. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 15 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Bayer). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| ARASTEP NCT05794906 · Bayer | high-risk biochemical recurrence of prostate cancer | Phase 3 | 177 | 18 | Standard | Nov 17, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ARASENS NCT02799602 · Bayer DeepView → | metastatic hormone-sensitive prostate cancer | Phase 3 | Deep | View | |||
| ARANOTE NCT04736199 · Bayer DeepView → | metastatic hormone-sensitive prostate cancer | Phase 3 | Deep | View | |||
| SOHO-01 NCT05099172 · Bayer DeepView → | advanced EGFR- and/or HER2-mutant non-small cell lung cancer | Phase 1/Phase 2 | Deep | View | |||
| ERA 223 NCT02043678 · Bayer DeepView → | chemotherapy-naïve bone-predominant metastatic castration-resistant prostate cancer | Phase 3 | Deep | View | |||
| ALSYMPCA NCT00699751 · Bayer DeepView → | castration-resistant prostate cancer with symptomatic bone metastases | Phase 3 | Deep | View | |||
| SOHO-02 NCT06452277 · Bayer DeepView → | first-line advanced NSCLC with HER2-activating mutations | Phase 3 | Deep | View | |||
| OASIS-4 NCT05587296 · Bayer DeepView → | vasomotor symptoms from endocrine therapy for breast cancer | Phase 3 | Deep | View | |||
| ARASEC NCT05059236 · Bayer StandardView → | metastatic hormone-sensitive prostate cancer | Phase 2 | Standard | View | |||
| FORT-2 NCT03473756 · Bayer StandardView → | cisplatin-ineligible FGFR-positive locally advanced or metastatic urothelial carcinoma | Phase 1 | Standard | View | |||
| RESORCE NCT01774344 · Bayer StandardView → | hepatocellular carcinoma after sorafenib | Phase 3 | Standard | View | |||
| FORT-1 NCT03410693 · Bayer StandardView → | FGFR-positive locally advanced or metastatic urothelial carcinoma | Phase 2/Phase 3 | Standard | View | |||
| NAVIGATE NCT02576431 · Bayer FocusedView → | NTRK fusion-positive solid tumors | Phase 2 | Focused | View | |||
| NCT02122913 NCT02122913 · Bayer FocusedView → | Not given | Phase 1 | Focused | View | |||
| SCOUT NCT02637687 · Bayer FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| NCT03215511 NCT03215511 · Bayer FocusedView → | previously treated NTRK fusion solid tumors | Phase 1 | Focused | View | |||